EU/3/17/1841: Orphan designation for the treatment of von Hippel-Lindau disease

propranolol hydrochloride


On 27 February 2017, orphan designation (EU/3/17/1841) was granted by the European Commission to Consejo Superior de Investigaciones Cientificas (CSIC), Spain, for propranolol hydrochloride for the treatment of von Hippel-Lindau disease.

Key facts

Active substance
propranolol hydrochloride
Intended use
Treatment of von Hippel-Lindau disease
Orphan designation status
EU designation number
Date of designation
Consejo Superior de Investigaciones Cientificas (CSIC)
C/ Serrano 142
28006 Madrid
Telephone: +34 91 568 15 31

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
1 rating